Goyal et al., 2022 - Google Patents
Analytical similarity assessment of MYL-1402O to reference BevacizumabGoyal et al., 2022
View PDF- Document ID
- 693957860356696845
- Author
- Goyal P
- Vats B
- Subbarao M
- Honnappa C
- Kabadi P
- Rohil S
- Bera A
- Mehta G
- Pai H
- Adhikari L
- Tagore R
- Sharma S
- Venkatachala R
- Nair P
- Annegowda S
- Sahu A
- Trivedi S
- Shastri N
- Gokhale Y
- Thomas R
- Thakur A
- Mohan D
- Rao K U
- Melarkode R
- Ullanat R
- Publication year
- Publication venue
- Expert Opinion on Biological Therapy
External Links
Snippet
Background Bevacizumab (BEV) is a recombinant humanized monoclonal immunoglobulin G1 antibody that binds to vascular endothelial growth factor (VEGF)-A and acts as an antiangiogenic agent. It is approved for treatment of many cancer indications, including …
- 108010005144 Bevacizumab 0 title abstract description 214
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/746—Erythropoetin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using infra-red, visible or ultra-violet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Seo et al. | Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumab | |
| Nupur et al. | Assessment of structural and functional similarity of biosimilar products: rituximab as a case study | |
| Hong et al. | Physicochemical and biological characterization of SB2, a biosimilar of Remicade®(infliximab) | |
| Cho et al. | Evaluation of the structural, physicochemical, and biological characteristics of SB4, a biosimilar of etanercept | |
| Magnenat et al. | Demonstration of physicochemical and functional similarity between the proposed biosimilar adalimumab MSB11022 and Humira® | |
| Xu et al. | Physicochemical and functional assessments demonstrating analytical similarity between rituximab biosimilar HLX01 and the MabThera® | |
| Nupur et al. | Analytical similarity assessment of biosimilars: global regulatory landscape, recent studies and major advancements in orthogonal platforms | |
| Lee et al. | Evaluation of analytical similarity between trastuzumab biosimilar CT-P6 and reference product using statistical analyses | |
| Kim et al. | Analytical characterization of coformulated antibodies as combination therapy | |
| Alam et al. | Deamidation can compromise antibody colloidal stability and enhance aggregation in a pH-dependent manner | |
| US20150147317A1 (en) | Methods related to bevacizumab | |
| Yu et al. | Analytical similarity of a proposed biosimilar BVZ-BC to bevacizumab | |
| Miao et al. | Physicochemical and biological characterization of the proposed biosimilar tocilizumab | |
| Schreiber et al. | Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab | |
| Wu et al. | Weak protein interactions and pH-and temperature-dependent aggregation of human Fc1 | |
| Seo et al. | Analytical and functional similarity of biosimilar ABP 798 with rituximab reference product | |
| Reichert et al. | European Medicines Agency workshop on biosimilar monoclonal antibodies: July 2, 2009, London, UK | |
| Xu et al. | Quality comparability assessment of a SARS-CoV-2-neutralizing antibody across transient, mini-pool-derived and single-clone CHO cells | |
| Goyal et al. | Analytical similarity assessment of MYL-1402O to reference Bevacizumab | |
| Song et al. | Monoclonal antibody higher order structure analysis by high throughput protein conformational array | |
| Singh et al. | Structural and functional comparability study of anti-CD20 monoclonal antibody with reference product | |
| Jiang et al. | Technical decision making with higher order structure data: higher order structure characterization during protein therapeutic candidate screening | |
| Hutterer et al. | Analytical similarity assessment of ABP 959 in comparison with eculizumab reference product | |
| Gurel et al. | Structural and functional analysis of CEX fractions collected from a novel avastin® biosimilar candidate and its innovator: a comparative study | |
| Hambly et al. | Detection and quantitation of IgG 1 hinge aspartate isomerization: a rapid degradation in stressed stability studies |